Racura Oncology Ltd has released a press release.
Bellberry Ethics Approval Activates New HARNESS Trial Sites
Earlier from Racura Oncology
- Racura Oncology Doses First Patient in Phase 1 HARNESS-1 Trial of RC220 in EGFR-Mutant Non-Small Cell Lung Cancer
- Racura Treats First Patient in HARNESS-1 Lung Cancer Trial
- Racura raised $34.3m to Advance Three Oncology Trials
- Emerging Companies Specialist Invests in Racura